[go: up one dir, main page]

AR061332A1 - OXADIAZOL COMPOUND AS INHIBITOR OF DGAT1 (DIACILGLICEROL ACILTRANSFERASA) - Google Patents

OXADIAZOL COMPOUND AS INHIBITOR OF DGAT1 (DIACILGLICEROL ACILTRANSFERASA)

Info

Publication number
AR061332A1
AR061332A1 ARP070102537A ARP070102537A AR061332A1 AR 061332 A1 AR061332 A1 AR 061332A1 AR P070102537 A ARP070102537 A AR P070102537A AR P070102537 A ARP070102537 A AR P070102537A AR 061332 A1 AR061332 A1 AR 061332A1
Authority
AR
Argentina
Prior art keywords
dgat1
diacilglicerol
aciltransferasa
inhibitor
oxadiazol
Prior art date
Application number
ARP070102537A
Other languages
Spanish (es)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR061332A1 publication Critical patent/AR061332A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

Se proporcionan nuevas formas cristalinas del compuesto ácido (trans-4-{4-[({5-[(3,4-difluorfenil)amino]-1,3,4-oxadiazol-2-il}carbonil)amino]fenil}ciclohexil)acético, junto con procesos para la elaboracion de dichas formas, composiciones farmacéuticas que las comprenden y el uso de tales formas en un tratamiento médico, que requiere inhibicion de DGAT1, diabetes, obesidad.New crystalline forms of the acid compound (trans-4- {4 - [({5 - [(3,4-difluorphenyl) amino] -1,3,4-oxadiazol-2-yl} carbonyl) amino] phenyl} are provided cyclohexyl) acetic, together with processes for the elaboration of said forms, pharmaceutical compositions that comprise them and the use of such forms in a medical treatment, which requires DGAT1 inhibition, diabetes, obesity.

ARP070102537A 2006-06-12 2007-06-11 OXADIAZOL COMPOUND AS INHIBITOR OF DGAT1 (DIACILGLICEROL ACILTRANSFERASA) AR061332A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0611552.1A GB0611552D0 (en) 2006-06-12 2006-06-12 Chemical compounds

Publications (1)

Publication Number Publication Date
AR061332A1 true AR061332A1 (en) 2008-08-20

Family

ID=36745696

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102537A AR061332A1 (en) 2006-06-12 2007-06-11 OXADIAZOL COMPOUND AS INHIBITOR OF DGAT1 (DIACILGLICEROL ACILTRANSFERASA)

Country Status (16)

Country Link
EP (1) EP2041101A1 (en)
JP (1) JP2009539954A (en)
KR (1) KR20090015980A (en)
CN (1) CN101466690A (en)
AR (1) AR061332A1 (en)
AU (1) AU2007259031A1 (en)
BR (1) BRPI0712354A2 (en)
CA (1) CA2653550A1 (en)
CL (1) CL2007001700A1 (en)
GB (1) GB0611552D0 (en)
IL (1) IL195348A0 (en)
MX (1) MX2008015762A (en)
NO (1) NO20084963L (en)
TW (1) TW200815378A (en)
UY (1) UY30404A1 (en)
WO (1) WO2007144571A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006064189A1 (en) 2004-12-14 2006-06-22 Astrazeneca Ab Oxadiazole derivatives as dgat inhibitors
EP1966221A1 (en) 2005-12-22 2008-09-10 AstraZeneca AB Pyrimido- [4, 5-]-oxazines for use as dgat inhibitors
AU2007245059B2 (en) 2006-03-31 2011-07-28 Novartis Ag New compounds
CN101460470B (en) 2006-05-30 2011-05-18 阿斯利康(瑞典)有限公司 1,3,4-oxadiazole derivatives as DGAT1 inhibitors
EP2041100B1 (en) 2006-05-30 2010-12-22 AstraZeneca AB Substituted 5- phenylamino- 1, 3, 4-oxadiaz0l-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme a diacylglycerol acyltransferase
EP2120911A1 (en) * 2007-02-15 2009-11-25 Prosidion Limited Amide and urea derivatives for the treatment of metabolic diseases
AR066169A1 (en) 2007-09-28 2009-07-29 Novartis Ag DERIVATIVES OF BENZO-IMIDAZOLES, USEFUL FOR DISORDERS ASSOCIATED WITH THE ACTIVITY OF DGAT
KR20100099738A (en) 2007-12-20 2010-09-13 아스트라제네카 아베 Carbamoyl compounds as dgat1 inhibitors 190
DK3366686T3 (en) 2009-03-20 2020-11-23 Metabasis Therapeutics Inc INHIBITORS OF DIACYLGLYCEROL-O-ACYLTRANSFERASE 1 (DGAT-1) AND USES THEREOF
EP2443096A1 (en) 2009-06-19 2012-04-25 AstraZeneca AB Pyrazine carboxamides as inhibitors of dgat1
FR2963005B1 (en) * 2010-07-23 2012-08-17 Sanofi Aventis DERIVATIVES OF OXADIAZOLES AND PYRIDAZINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR044152A1 (en) * 2003-05-09 2005-08-24 Bayer Corp RENTAL DERIVATIVES, METHOD OF PREPARATION AND USE FOR THE TREATMENT OF OBESITY
WO2006064189A1 (en) * 2004-12-14 2006-06-22 Astrazeneca Ab Oxadiazole derivatives as dgat inhibitors

Also Published As

Publication number Publication date
JP2009539954A (en) 2009-11-19
KR20090015980A (en) 2009-02-12
TW200815378A (en) 2008-04-01
IL195348A0 (en) 2009-08-03
AU2007259031A1 (en) 2007-12-21
BRPI0712354A2 (en) 2012-06-05
CL2007001700A1 (en) 2008-01-18
WO2007144571A1 (en) 2007-12-21
CA2653550A1 (en) 2007-12-21
MX2008015762A (en) 2009-03-16
CN101466690A (en) 2009-06-24
NO20084963L (en) 2009-01-07
GB0611552D0 (en) 2006-07-19
EP2041101A1 (en) 2009-04-01
UY30404A1 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
AR061332A1 (en) OXADIAZOL COMPOUND AS INHIBITOR OF DGAT1 (DIACILGLICEROL ACILTRANSFERASA)
CL2011002697A1 (en) Compounds derived from 3- [4- (oxo-dihydropyridin) benzyl] -1,3-oxazin-one hydrated, 11beta-hsd1 inhibitors; pharmaceutical composition comprising them; and its use in the treatment of diabetes
CL2008002998A1 (en) Piperazine-1-carboxamide derived compounds, faah inhibitor; pharmaceutical composition comprising said compound; and use of the compound for the treatment of inflammatory or neuropathic pain, anxiety and depression.
AR118922A2 (en) PROCESSES FOR THE PREPARATION OF 1,2,4-OXADIAZOLE BENZOIC ACIDS
CL2011001389A1 (en) Isoxazoline derivative compounds; composition comprising one of the compounds; and use of the compounds in parasite control.
CL2008001170A1 (en) Compounds derived from chromans and naphthalene substituted with a heterocyclic ring; pharmaceutical composition; and its use in the treatment of acute or chronic nociceptive pain or pain, visceral pain, inflammatory and / or central or peripheral neuropathic pain.
SV2009002865A (en) USE OF OXAZOLIDINONES FOR THE TREATMENT AND PROFILAXIS OF MICROANGIOPATIAS
BR112012002134B8 (en) apaf-1 inhibitor compounds
GT201200316A (en) CRYSTAL FORM OF 4- [5- [3-CHLORINE-5- (TRIFLUOROMETIL) PHENYL] -4,5-DIHYDRO-5- (TRIFLUOROMETIL) -3-ISOXAZOLIL-N- [2-0X0-2- [(2, 2, -TRIFLUOROETIL) AMINO] ETIL] -1-NAFTALENOCARBOXAMIDA
UY29384A1 (en) ACID DERIVATIVES 2-3S, 4R) -4 - (((3,4-DICLORO-5-METHYL-1H-PIRROL-2-IL) CARBONIL) AMINO) -1,3-TIAZOL-5-CARBOXYL AND ITS SALTS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, PREPARATION PROCEDURES AND APPLICATIONS.
CL2009000483A1 (en) Compounds derived from n- (pyridin-3-yl) -1,3-thiazole-5-amino-4-carboxamide, pim kinase inhibitors; pharmaceutical composition; and use for the treatment of cancer.
CL2008000946A1 (en) COMPOUNDS DERIVED FROM PIRROLOPIRIMIDINA, INHIBITORS OF CIANASA JAK3; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF REPLACEMENT OF TRANSPLANTS, AUTOIMMUN DISEASES
GT200900260A (en) ANTICOAGULANT CONVINTION THERAPY WITH A COMPOUND THAT ACTS AS AN INHIBITOR OF THE XA FACTOR
CL2007002967A1 (en) CRYSTAL FORM A OF THE COMPOUND 4- [3- (4-CYCLOPROPANCARBONIL-PIPERAZIN-1-CARBONIL) -4-FLUORO-BENCIL] -2H-FTALAZIN-1-ONA; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND IN THE TREATMENT OF A
IL199673A0 (en) 5-(1,3,4- oxadiazol-2-yl)-1h-indazole and 5-(1,3,4 thiadiazol-2-yl)-1h-indazole derivatives as sgk inhibitors for the treatment of diabetes
ECSP10010561A (en) PYRIMIDIN-5-SUBSTITUTED CARBOXAMIDS 281
CL2010001483A1 (en) Compounds derived from 5-phenyl-1h-pyridin-2-one and 6-phenyl-2h-pyridazin-3-one, tyrosine kinase inhibitors (btk); Pharmaceutical composition comprising said compounds and their use for the treatment of an inflammatory and / or autoimmune pathological state.
CL2007003202A1 (en) COMPOUNDS DERIVED FROM ESPIROINDOLINONA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF CELL PROLIFERATION DISORDERS.
CL2009000915A1 (en) Compounds derived from 1-cyano-3-pyrrolidinyl-benzenesulfonamides, cathepsin c inhibitors; pharmaceutical composition comprising said compound; and use of the compound for the treatment of a chronic obstructive pulmonary disease (copd).
CL2009000914A1 (en) Compounds derived from 1-cyano-3-pyrrolidinyl-n-substituted-sulfonamides, cathepsin c inhibitors; pharmaceutical composition comprising said compound; and use of the compound for the treatment of a chronic obstructive pulmonary disease.
PE20100083A1 (en) DRUG COMBINATIONS INCLUDING A DGAT INHIBITOR AND A PPAR AGONIST
UY30298A1 (en) C-FMS II QUINASE INHIBITORS
CL2008002430A1 (en) Benzenesulfonamide derived compounds, cathepsin c inhibitors; pharmaceutical composition comprising them; and its use for the treatment of copd.
CL2009000004A1 (en) Crystal form of r-2- (4-cyclopropanesulfonyl-phenyl) -n-pyrazin-2-yl-3- (tetrahydropyran-4-yl) -propionamide; pharmaceutical composition comprising said crystalline form; and use for the treatment of diabetes or hyperglycemia.
CL2008002038A1 (en) Compounds derived from 3-phenyl-1,2-oxazole, sodium channel inhibitors; and its use for the treatment of a pain disorder.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal